Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com - UBS maintained its Buy rating and $18.00 price target on Perspective Therapeutics Inc (NYSE:CATX), currently trading at $3.56 with a market cap of $264 million, following the company’s second-quarter 2025 results, which highlighted enrollment progress in its VMT-a-NET Phase 1/2a trial for neuroendocrine tumors. According to InvestingPro data, analyst consensus remains strongly bullish, with price targets ranging from $5 to $20.50.
The company reported that 39 additional patients were treated at the 5 mCi dose level (Cohort 2), with 11 patients reaching at least 32 weeks of follow-up as of July 31st. These 11 patients are expected to have approximately 38-45 weeks of follow-up by the time updated trial data is presented at the European Society for Medical (TASE:BLWV) Oncology (ESMO) conference on October 20th.
UBS noted that this follow-up duration should be sufficient to capture most potential responses, as previous patient responses in the trial occurred between 36-48 weeks. The firm identified a 50% objective response rate as a key benchmark for the upcoming data presentation, comparing it to RadioMedix’s 212Pb-DOTAMTATE, which showed a 56% response rate.
Perspective Therapeutics has seen improved investor sentiment over the past six months, with the stock gaining nearly 29% during this period, supported by continued clinical validation from existing Cohort 2 patients and FDA approval to proceed with higher dosing in Cohort 3. InvestingPro analysis shows the company holds more cash than debt, though it’s currently rated as having weak financial health. Get access to 10+ additional ProTips and comprehensive analysis with InvestingPro.
UBS believes the Lead-based radiopharmaceutical assets in Perspective’s pipeline could demonstrate superior efficacy and safety compared to current standard-of-care beta-emitting radiopharmaceuticals. Based on InvestingPro’s Fair Value analysis, the stock currently appears fairly valued. Discover the complete financial picture with InvestingPro’s comprehensive research report, available for 1,400+ US stocks.
In other recent news, Perspective Therapeutics announced that it will present updated data from its [212Pb]VMT-α-NET program at the European Society of Medical Oncology Congress in October 2025. The presentation will include safety and efficacy data from the first two dose-finding cohorts of their clinical trial. This follows the company’s second-quarter 2025 financial results, which prompted Oppenheimer to lower its price target for Perspective Therapeutics to $14, while maintaining an Outperform rating. Conversely, RBC Capital raised its price target to $16, citing competitive objective response rates and safety data from the company’s NET program presented at the American Society of Clinical Oncology. Additionally, Perspective Therapeutics disclosed the results of its 2025 Annual Meeting of Stockholders, where a quorum was reached with 82.17% of shares represented. Key decisions included the election of five board members, with Lori A. Woods receiving the most votes. These developments reflect ongoing activities and strategic decisions within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.